Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 2/20 | 0.82 |
| ▸ | DRD4 | P21917 | 14/20 | 0.71 |
| ▸ | DRD2 | P14416 | 6/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6397461 | 0.99 | CCR3 (0.81) | CCR3DRD4DRD2CYP1A2CYP3A4 | |
| SCHEMBL5658825 | 0.90 | CCR3 (1.00) | CCR3DRD4DRD2CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL6399917 | 0.90 | CCR3 (0.98) | CCR3DRD4DRD2CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL6403181 | 0.86 | DRD4 (0.72) | CCR3DRD4DRD2CYP1A2CYP3A4 | |
| SCHEMBL1322020 | 0.83 | DRD4 (1.00) | DRD4DRD2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6397066 | 0.81 | CCR3 (0.81) | CCR3DRD4MAPTSLC5A7 | |
| SCHEMBL27550778 | 0.81 | CCR3 (0.83) | CCR3DRD4DRD2CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL5659060 | 0.81 | CCR3 (0.82) | CCR3DRD4DRD2CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL6397246 | 0.81 | CCR3 (0.82) | CCR3DRD4DRD2SLC5A7 | |
| Hydrochloric Acid SCHEMBL6397090 | 0.80 | CCR3 (0.79) | CCR3DRD4SLC5A7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030134840-A1 | Novel compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2003-07-17 | — | — | US | claimed |
| US-6518286-B1 | Piperidinyl compounds for modulation of immune and inflammatory responses in various diseases and disorders, including asthma | ASTRAZENECA AB (SE) | 2003-02-11 | — | — | US | claimed |
| CN-1344266-A | Novel compounds | ASTRAZENECA AB (SE) | 2002-04-10 | — | — | CN | claimed |
| US-6946478-B2 | Compounds | ASTRAZENECA AB (SE) | 2005-09-20 | — | — | US | disclosed |
| US-20030134840-A1 | Novel compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2003-07-17 | — | — | US | disclosed |
| CN-1344266-A | Novel compounds | ASTRAZENECA AB (SE) | 2002-04-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134840-A1 | Novel compounds | RPS4X, RPS4Y1, CYP4B1 | CCR3 894/4885DRD4 162/4885DRD2 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.